14 reports

Neuroblastoma (NB)- Epidemiology Forecast to 2027 ##.

  • Cancer
  • France
  • Germany
  • Italy
  • Spain

Emerging diagnostic technologies and their potential market applications.

  • Cancer
  • Pathology
  • Spain
  • Market Shares

Emerging diagnostic technologies and their potential market applications.

  • Cancer
  • Pathology
  • Spain
  • Demand

We' re getting a lot more biomarker-based treatments than just having diagnostic-based treatment.

  • Cancer
  • Spain
  • Bristol-Myers Squibb Company
  • Novartis AG
  • PROVENGE group
  • 3.4.7 Mutations (17p deletion, 11q Deletion, and TP53) Among the Diagnosed Incident Cases of CLL

LEUKEMIA; ##(##):##-##.

  • Cancer
  • Epidemiology
  • Hospital
  • Leukemia
  • Spain

STILL, PSA TESTING REMAINS A WIDELY AVAILABLE DIAGNOSTIC OPTION.

  • Cancer
  • Pathology
  • Prostate Cancer
  • Spain
  • Forecast
  • 3.4 FORECAST METHODOLOGY

[Accessed November ##, 2015].

  • Cancer
  • Lymphoma
  • Pathology
  • Spain
  • Forecast
  • FEB 16, 2018: SPANISH CENTER SANTIAGO DE COMPOSTELA JOINS THE LARGEST EVER PROSPECTIVE STUDY INTO FAMILIAL RISK OF DEVELOPING PANCREATIC CANCER

IMMRAY™ IS A TECHNOLOGY PLATFORM FOR THE DEVELOPMENT OF DIAGNOSTIC TESTS AND THE COMPANY' S PRIMARY TEST.

  • Cancer
  • Hospital
  • Pancreatic Cancer
  • Spain
  • Product Initiative
  • 05/06/2016: EARLY DIAGNOSIS, A MULTIDISCIPLINARY APPROACH AND ACCESS TO NEW THERAPIES, KEY IN THE TREATMENT OF OVARIAN CANCER

The exchange ratio between the shares of the two companies was ##:##, one Pharma Mar share for each Zeltia share.

  • Breast Cancer
  • Cancer
  • Spain
  • Company
  • Pharma Mar, S.A.
  • Bioprognos SL Pipeline Products and Ongoing Clinical Trials Overview

North America: +## ## ## ## Europe: Asia Pacific: +## ## ## ## Email: info@globaldata. com DISCLAIMER +## (##) ## ## ## (OR) +## ## ## ##

  • Cancer
  • Spain
  • United States
  • Company
  • Product Initiative
  • Personalized Medicine Test - Acute Lymphocytic Leukemia - Product Status
  • Indication

Notes Ongoing, Recruiting Ongoing, not Recruiting Ongoing, Recruiting by invitation Ongoing, not yet recruiting Recent Development section covers news posted during last one year GlobalData considers regulatory approved (Approved and Issued) products as pipeline in case products are yet to

  • Biotech
  • Cancer
  • Spain
  • Company
  • Product Initiative
  • Prognostic Test - Colorectal Cancer - Product Status
  • Sep 14, 2011: Oryzon Genomics To Launch GynEC Dx Non Invasive Test For Detection Of Endometrial Cancer

From 2008 to 2010, Dr Greig was also President of SR One, GSK' s Corporate Venture Group.

  • Cancer
  • Genomics
  • Spain
  • Company
  • Oryzon Genomics S.A.

(Roche) is a research-focused healthcare company that provides biopharmaceuticals, cancer medicines and in vitro diagnostics (IVD) systems.

  • Cancer
  • Spain
  • World
  • Product Initiative
  • Oryzon Genomics S.A.

Oxford Immunotec Global Plc (OIG) is a global, commercial-stage diagnostics company.

  • Cancer
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Spain